USANA Health Sciences (USNA) Projected to Announce Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is anticipated to release its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect USANA Health Sciences to announce earnings of $0.43 per share and revenue of $235.0030 million for the quarter. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 11:00 AM ET.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.17. The company had revenue of $250.22 million during the quarter, compared to the consensus estimate of $240.99 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%. On average, analysts expect USANA Health Sciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Stock Performance

Shares of NYSE USNA opened at $22.07 on Friday. The business’s 50-day simple moving average is $20.45 and its 200-day simple moving average is $19.76. USANA Health Sciences has a 52 week low of $16.60 and a 52 week high of $32.32. The firm has a market cap of $407.38 million, a price-to-earnings ratio of 46.95, a P/E/G ratio of 0.87 and a beta of 0.73.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on USNA shares. Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. Finally, Wall Street Zen upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, USANA Health Sciences presently has an average rating of “Reduce”.

Insiders Place Their Bets

In other USANA Health Sciences news, insider Joshua Foukas sold 3,791 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $19.82, for a total value of $75,137.62. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Brent Neidig sold 5,002 shares of USANA Health Sciences stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total value of $97,288.90. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 17,660 shares of company stock valued at $336,579. Company insiders own 0.82% of the company’s stock.

Institutional Trading of USANA Health Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC raised its position in shares of USANA Health Sciences by 72.8% during the fourth quarter. Hsbc Holdings PLC now owns 13,334 shares of the company’s stock valued at $259,000 after buying an additional 5,617 shares during the last quarter. State of Tennessee Department of Treasury grew its position in USANA Health Sciences by 307.8% during the fourth quarter. State of Tennessee Department of Treasury now owns 29,290 shares of the company’s stock worth $636,000 after buying an additional 22,108 shares in the last quarter. Empowered Funds LLC grew its position in USANA Health Sciences by 10.6% during the fourth quarter. Empowered Funds LLC now owns 60,437 shares of the company’s stock worth $1,186,000 after buying an additional 5,782 shares in the last quarter. Tudor Investment Corp ET AL increased its stake in USANA Health Sciences by 354.8% during the fourth quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock valued at $2,153,000 after acquiring an additional 85,570 shares during the period. Finally, Numerai GP LLC bought a new position in USANA Health Sciences during the fourth quarter valued at about $1,027,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.